Praxis Precision Medicines
MA · 4 filings, 2025
Lobbying spend · 2025
$160K
to shape legislation
About the organization
Ulixacaltamide (developmental codes PRAX-944 and Z-944) is an investigational new drug developed by Praxis Precision Medicines for the treatment of essential tremor (ET). It is a small molecule designed to selectively inhibit T-type calcium channels, reducing the abnormal neuronal burst firing in the cerebello-thalamo-cortical (CTC) circuit that is believed to cause tremors. via Wikipedia ↗
1Lobbies on
Its filings list: Pharmacy
2Through these firms · 1
THE KPM GROUP DC LLC
3Bills moving in its lanes
No bill names this company outright; these are recent bills in the sectors it lobbies.
- S 5225A bill to amend the Elementary and Secondary Education Act of 1965 to include certain curriculum expenses a…
- S 5232A bill to amend the Public Health Service Act to authorize rural residency planning and development grant p…
- S 5237A bill to require the Director of the National Institute of Allergy and Infectious Diseases to award a comp…
- S 5242A bill to provide for digital communication of prescribing information for drugs (including biological prod…
- HR 10033Rules for self-driving cars and emergency crews